An Observational Study of Ckd with Anaemia in Tertiary Care Centre
Authors/Creators
- 1. Assistant Professor Department of Medicine ESICMCH Sanathnagar
- 2. Professor Department of Medicine MRIMS Suraram
- 3. Senior Resident Department of Medicine ESICMCH Sanathnagar
Description
Background: Iron deficiency anaemia is the leading cause of heart failure in ckd patients. this study was done to study the incidence of heart failure in diabetic kidney disease patients in government general hospital. Materials and Methods: This Prospective Observational study was done for one year in tertiary care Hospital. A total of 100 cases male and female admitted for dialysis were studied based on inclusion and exclusion criteria. All patients were done routine investigations including iron studies, urine for microalbuminuria, 2 decho and thoroughly elicited for history of diabetes. Patients below 12 years, pregnant women and patients with previous bleeding manifestations and heart ailments prior to onset of diabetes were excluded from the study. The study was carried out in all patients fulfilling the inclusion and exclusion criteria. Results: A total of 100 patients 60 males and 40 females presented during the study period. Heart failure was more prevalent in diabetics in age group of 40-60 years.[>60yrs. [25] > 60 yrs [20], 20-40 yrs[8] out of these DM > 5YRS were 4 in 20-40 yrs,16in 40-60 yrs,18 in > 60 yrs. Microalbuminuria was present in 4 patients in 20-40 yrs,16 patients in 40-60 yrs,18 in >60 yrs age group with abnormal renal parameters. IDA was present in 12 patients in 20-40 yrs, 40 patients in 40-60 yrs, and 10 patients in > 60 yrs. Conclusion: It was Observed from the study that ida was leading cause of heart failure in patients with ckd. Even in those patients without prolonged dm history. anaemia was leading to heart failure with microalbuminuria.
Abstract (English)
Background: Iron deficiency anaemia is the leading cause of heart failure in ckd patients. this study was done to study the incidence of heart failure in diabetic kidney disease patients in government general hospital. Materials and Methods: This Prospective Observational study was done for one year in tertiary care Hospital. A total of 100 cases male and female admitted for dialysis were studied based on inclusion and exclusion criteria. All patients were done routine investigations including iron studies, urine for microalbuminuria, 2 decho and thoroughly elicited for history of diabetes. Patients below 12 years, pregnant women and patients with previous bleeding manifestations and heart ailments prior to onset of diabetes were excluded from the study. The study was carried out in all patients fulfilling the inclusion and exclusion criteria. Results: A total of 100 patients 60 males and 40 females presented during the study period. Heart failure was more prevalent in diabetics in age group of 40-60 years.[>60yrs. [25] > 60 yrs [20], 20-40 yrs[8] out of these DM > 5YRS were 4 in 20-40 yrs,16in 40-60 yrs,18 in > 60 yrs. Microalbuminuria was present in 4 patients in 20-40 yrs,16 patients in 40-60 yrs,18 in >60 yrs age group with abnormal renal parameters. IDA was present in 12 patients in 20-40 yrs, 40 patients in 40-60 yrs, and 10 patients in > 60 yrs. Conclusion: It was Observed from the study that ida was leading cause of heart failure in patients with ckd. Even in those patients without prolonged dm history. anaemia was leading to heart failure with microalbuminuria.
Files
IJPCR,Vol15,Issue6,Article279.pdf
Files
(388.7 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:9bedead69d2d2fe158435bc1b2de1129
|
388.7 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-05-05
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/15/IJPCR,Vol15,Issue6,Article279.pdf
- Development Status
- Active
References
- 1. Cappellini MD, Comin‐Colet J, De Francisco A, Dignass A, Doehner W, Lam SP, Macdougall IC, Rogler G, Camaschella C, Kadir R, Kassebaum NJ, Spahn DR, Taher AT, Musallam KM. Iron deficiency across chronic inflammatory conditions: international expert opinion on definition, diagnosis, and management. Am J Hematol 2017; 92: 1068– 1078. 2. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin‐Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJ, Anker SD, Ponikowski P. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010; 31: 1872– 1880. 3. Klip IT, Comin‐Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok DJ, Rosentryt P, Torrens A, Polonski L, van Veldhuisen DJ, van der Meer P, Jankowska EA. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 2013; 165: 575– 582. 4. Okonko DO, Mandal AK, Missouris CG, Poole‐Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am CollCardiol 2011; 58: 1241– 1251. 5. Peyrin‐Biroulet L, Williet N, Cacoub P. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J ClinNutr 2015; 102: 1585– 1594. 6. Scholar Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 2013; 34: 816– 829. 7. McDonagh T, Macdougall IC. Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral? Eur J Heart Fail 2015; 17: 248– 262. 8. Toblli JE, Lombrana A, Duarte P, Di Gennaro F. Intravenous iron reduces NT‐pro‐brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am CollCardiol 2007; 50: 1657– 1665. 9. Avni T, Leibovici L, Gafter‐Gvili A. Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta‐analysis. Eur J Heart Fail 2012; 14: 423– 429. 10. Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin‐ Colet J, Ruschitzka F, Luscher TF, Arutyunov GP, Motro M, Mori C, Roubert B, Pocock SJ, Ponikowski P. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron‐deficient heart failure patients: an individual patient data meta‐analysis. Eur J Heart Fail 2018; 20: 125– 133. 11. Jankowska EA, Tkaczyszyn M, Suchocki T, Drozd M, von Haehling S, Doehner W, Banasiak W, Filippatos G, Anker SD, Ponikowski P. Effects of intravenous iron therapy in iron‐ deficient patients with systolic heart failure: a meta‐analysis of randomized controlled trials. Eur J Heart Fail 2016; 18: 786– 795.12. Enjuanes C, Bruguera J, Grau M, Cladellas M, Gonzalez G, Merono O, Moliner‐Borja P, Verdu JM, Farre N, Comin‐Colet J. Iron status in chronic heart failure: impact on symptoms, functional class and submaximal exercise capacity. Rev EspCardiol (Engl Ed) 2016; 69: 247– 255. 13. Anker SD, Comin CJ, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart RB, Pocock SJ, Poole‐ Wilson PA, Ponikowski P. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436– 2448. 14. van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Bohm M, Doletsky A, Voors AA, Macdougall IC, Anker SD, Roubert B, Zakin L, Cohen‐Solal A. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation 2017; 136: 1374– 1383. 15. Ponikowski P, van Veldhuisen DJ, Comin‐Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD. Beneficial effects of long‐term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015; 36: 657– 658. 16. Comin‐Colet J, Enjuanes C, Gonzalez G, Torrens A, Cladellas M, Merono O, Ribas N, Ruiz S, Gomez M, Verdu JM, Bruguera J. Iron deficiency is a key determinant of health‐related quality of life in patients with chronic heart failure regardless of anaemia status. Eur J Heart Fail 2013; 15: 1164– 1172. 17. Enjuanes C, Klip IT, Bruguera J, Cladellas M, Ponikowski P, Banasiak W, van Veldhuisen DJ, van der MP, Jankowska EA, Comin‐Colet J. Iron deficiency and health‐related quality of life in chronic heart failure: results from a multicenter European study. Int J Cardiol 2014; 174: 268– 275. 18. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez‐Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.Eur Heart J 2016; 37: 2129– 2200. 19. H.F. Groenveld, J.L. Januzzi, K. Damman, J. van Wijngaarden, H.L. Hillege, D.J. van Veldhuisen, et al. Anemia and mortality in heart failure patients a systematic review and metaanalysis. J Am Coll Cardiol, 2008;52: 818-827. 20. J.A. Ezekowitz, F.A. McAlister, P.W. Armstrong. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12065 patients with new-onset heart failure. Circulation, Medline. 2003; 107: 223-225. 21. C. Díez-López, J. Lupón, M. de Antonio, E. Zamora, M. Domingo, J. Santesmases, et al. Hemoglobin kinetics and long-term prognosis in heart failure. Rev Esp Cardiol Engl Ed, 2016;69:. 820-826 22. S.M. Bagshaw, D.N. Cruz, N. Aspromonte, L. Daliento, F. Ronco, G. Sheinfeld, et al. Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI consensus conference. Nephrol Dial Transpl, 2010; 25: 1406-1416 23. A.S. Go, J. Yang, L.M. Ackerson, K. Lepper, S. Robbins, B.M. Massie, et al. Hemoglobin level, chronic kidneydisease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization. ANCHOR Study. Circulation, Medline. 2006;113: 2713- 2723. 24. R.K. Spence. The economic burden of anemia in heart failure. Heart Fail Clin, 2010;6: 373-383 25. Al-Ahmad, W.M. Rand, G. Manjunath, M.A. Konstam, D.N. Salem, A.S. Levey, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol, Medline. 2001;38: 955-962. 26. E.A. Jankowska, S. von Haehling, S.D. Anker, I.C. Macdougall, P. Ponikowski. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J, 2013;34: 816-826. 27. Cohen-Solal, C. Leclercq, G. Deray, S. Lasocki, J.J. Zambrowski, A. Mebazaa, et al. Iron deficiency: an emerging therapeutic target in heart failure. Heart, 2014;100: 1014-1029 28.Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, BorodulinNadziejaBanasiak W, Polonski L, Filippatos G, McMurray JJ, Anker SD, Ponikowski P. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010 Aug;31(15):1872-80.